T2 Biosystems, Inc., a pioneering company in the field of molecular diagnostics, is headquartered in the United States. Founded in 2006, T2 Biosystems has established itself as a leader in the development of innovative diagnostic solutions, particularly in the areas of sepsis and infectious diseases. The company’s flagship products, including the T2Dx® Instrument and T2Candida® Panel, utilise advanced technology to deliver rapid and accurate results, setting them apart in the competitive diagnostics market. With a strong focus on improving patient outcomes, T2 Biosystems has achieved significant milestones, including FDA clearances and partnerships with major healthcare institutions. Their commitment to transforming the diagnostic landscape positions them as a key player in the industry, dedicated to enhancing clinical decision-making and patient care.
How does T2 Biosystems, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
T2 Biosystems, Inc.'s score of 23 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
T2 Biosystems, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and formal commitments suggests that T2 Biosystems may not yet have established a comprehensive framework for addressing its carbon footprint or climate impact. In the context of the industry, many companies are increasingly adopting science-based targets and sustainability initiatives to mitigate climate change. However, without specific commitments or data, T2 Biosystems' position on climate action remains unclear. As the company evolves, it may consider aligning with industry standards and frameworks to enhance its environmental responsibility and transparency.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
T2 Biosystems, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

